References
1. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017 Oct 10;17(1):230. doi: 10.1186/s12877-017-0621-2. PMID: 29017448; PMCID: PMC5635569.
2. Medication Safety in Polypharmacy. Geneva: World Health Organization; 2019 (WHO/UHC/SDS/2019.11). Licence: CC BY-NC-SA 3.0 IG. URL: https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11 Accessed: 01/07/2022
3. Rawle MJ, Richards M, Davis D, Kuh D. The prevalence and determinants of polypharmacy at age 69: a British birth cohort study. BMC Geriatr. 2018 May 16;18(1):118. doi: 10.1186/s12877-018-0795-2. PMID: 29769020; PMCID: PMC5956732.
4. Nguyen JK, Fouts MM, Kotabe SE, Lo E. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother. 2006 Mar;4(1):36-41. doi: 10.1016/j.amjopharm.2006.03.002. PMID: 16730619.
5. Rawle MJ, Cooper R, Kuh D, Richards M. Associations Between Polypharmacy and Cognitive and Physical Capability: A British Birth Cohort Study. J Am Geriatr Soc. 2018 May;66(5):916-923. doi: 10.1111/jgs.15317. Epub 2018 Mar 24. PMID: 29574684; PMCID: PMC6001617.
6. Spaniolas, Konstantinos MD; Cheng, Julius D. MD, MPH; Gestring, Mark L. MD; Sangosanya, Ayodele MD; Stassen, Nicole A. MD; Bankey, Paul E. MD Ground Level Falls Are Associated With Significant Mortality in Elderly Patients, The Journal of Trauma: Injury, Infection, and Critical Care: October 2010 - Volume 69 - Issue 4 - p 821-825. doi: 10.1097/TA.0b013e3181efc6c6
7. Cartagena LJ, Kang A, Munnangi S, et al. Risk factors associated with in-hospital mortality in elderly patients admitted to a regional trauma center after sustaining a fall. Aging Clin Exp Res. 2017 Jun;29(3):427-433. doi: 10.1007/s40520-016-0579-5. Epub 2016 May 3. PMID: 27142683.
8. Fadare JO, Obimakinde AM, Aina FO, Araromi EJ, et al. Anti-Cholinergic Drug Burden Among Ambulatory Elderly Patients in a Nigerian Tertiary Healthcare Facility. Front Pharmacol. 2021 Jan 29;12:580152. doi: 10.3389/fphar.2021.580152. PMID: 33584317; PMCID: PMC7878669.
9. Tan MP, Tan GJ, Mat S, Luben RN, Wareham NJ, Khaw KT, Myint PK. Use of Medications with Anticholinergic Properties and the Long-Term Risk of Hospitalization for Falls and Fractures in the EPIC-Norfolk Longitudinal Cohort Study. Drugs Aging. 2020 Feb;37(2):105-114. doi: 10.1007/s40266-019-00731-3. PMID: 31808140; PMCID: PMC7115837.
10. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013 Jul;9(4):377-85. doi: 10.1016/j.jalz.2012.02.005. Epub 2012 Nov 22. PMID: 23183138; PMCID: PMC3674201.
11. Tannenbaum C, Paquette A, Hilmer S, Holroyd-Leduc J, Carnahan R. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging. 2012 Aug 1;29(8):639-58. doi: 10.1007/BF03262280. PMID: 22812538.
12. Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell NL, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ. 2018 Apr 25;361:k1315. doi: 10.1136/bmj.k1315. Erratum in: BMJ. 2019 Oct 31;367:l6213. PMID: 29695481; PMCID: PMC5915701.
13. Onder G, Liperoti R, Fialova D, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci. 2012 Jun;67(6):698-704. doi: 10.1093/gerona/glr233. Epub 2012 Jan 4. PMID: 22219520.
14. Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML. Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc (2003). 2017 Nov-Dec;57(6):729-738.e10. doi: 10.1016/j.japh.2017.06.002. Epub 2017 Aug 5. PMID: 28784299.
15. Fox C, Richardson K, Maidment ID, et al. Anticholinergic medication use and cognitive impairment in the older population: the medical research council cognitive function and ageing study. J Am Geriatr Soc. 2011 Aug;59(8):1477-83. doi: 10.1111/j.1532-5415.2011.03491.x. Epub 2011 Jun 24. PMID: 21707557.
16. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-Brain Barrier: From Physiology to Disease and Back. Physiol Rev. 2019 Jan 1;99(1):21-78. doi: 10.1152/physrev.00050.2017. PMID: 30280653; PMCID: PMC6335099.
17. Hopewell S, Copsey B, Nicolson P, Adedire B, Boniface G, Lamb S. Multifactorial interventions for preventing falls in older people living in the community: a systematic review and meta-analysis of 41 trials and almost 20 000 participants. Br J Sports Med. 2020 Nov;54(22):1340-1350. doi: 10.1136/bjsports-2019-100732. Epub 2019 Aug 21. PMID: 31434659; PMCID: PMC7606575.
18. Soundararajan, K., & Balchandra, P. (2021). Staff Awareness of Anti-Cholinergic Burden (ACB) - A Qualitative Cross-Sectional Study in a Tertiary Care Hospital. Cureus , 13 (3), e14141. https://doi.org/10.7759/cureus.14141
19. Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M. Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol. 2021 Feb;77(2):147-162. doi: 10.1007/s00228-020-02994-x. Epub 2020 Oct 3. PMID: 33011824; PMCID: PMC7803697.
20. NICE. Falls: assessment and prevention of falls in older people. (CG161). London: NICE, 2013. URL: http://www.nice.org.uk/guidance/cg161 (assessed 01/07/2022)